Zydus gets China NMPA approval for Venlafaxine ER Capsules

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹947.10

prior close

₹937.65

announcement price

In-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.4%-1.3% vs market

Pharmaceuticals peers, median of 157sector-0.2%-0.7% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty 100 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.7

15m

+0.5

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+0.4-1.3-0.2-0.7

Next day

+0.4+1.0-0.6+0.5-0.1

-0.2+1.0-1.2+0.6-0.8

-0.3+1.1-1.4+0.5-0.8

-1.3+1.6-2.8+0.4-1.7

-1.6+1.1-2.7-0.6-1.0

-1.9+2.0-3.9-1.1-0.8

15d

-0.6+1.4-2.0-2.1+1.5

-2.3+0.7-3.0-3.2+0.8

-5.3+0.5-5.8-5.9+0.6

-5.1+1.4-6.5-6.4+1.3

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences received approval from China's NMPA for Venlafaxine Extended-Release Capsules in 75 mg and 150 mg strengths. The medicine treats Major Depressive Disorder, Generalised Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder. Production will happen at the company's Moraiya, Ahmedabad facility. This is the group's first approval from NMPA in China, opening access to the Chinese pharmaceutical market.

Likely market impact

Opens entry into the large China pharma market. First NMPA approval signals future pipeline expansion in the region. Marginally positive for the stock.